All In MedTech

FDA Clearance Tracker · P020045-S098

Freezor Cardiac Cryoablation Catheter, Freezor Xtra Cardiac Cryoablation Catheter

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Feb 18, 2022 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Feb 18, 2022

Approved

Time to decision

214 days

Received Jul 19, 2021. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P020045-S098
Device name
Freezor Cardiac Cryoablation Catheter, Freezor Xtra Cardiac Cryoablation Catheter
Applicant location
Mounds View, MN
Received
Jul 19, 2021
Decided
Feb 18, 2022
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P020045

Device type

Device class
Class III

Every decision under product code LPB

FDA's approval statement

As written in FDA's record.

Approval to expand the indication for use statement for the Freezor and Freezor Xtra Cardiac Cryoablation Catheters for use with pediatric patients.

Source documents

Other decisions for Medtronic Cryocath, LP

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

3 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.